



## Tumour Angiogenesis

Guest Editor:

**Dr. Ruowen Ge**

Department of Biological  
Sciences, National University of  
Singapore, Singapore 117558,  
Singapore

Deadline for manuscript  
submissions:

**closed (30 April 2013)**

### Message from the Guest Editor

Dear Colleagues,

Tumor angiogenesis is critical for both tumor progression and metastasis. Hence targeting tumor angiogenesis as a therapeutic anticancer approach has been actively pursued for many years. Despite the initial success in animal tumor models and some degree of effectiveness in prolonging the survival of human cancer patients, limitations of efficacy plus inherent as well as acquired resistance in human cancers still plague this therapeutic approach. Hence, further understanding of the molecular and cellular mechanisms of tumor angiogenesis are essential for the advancement of effective antiangiogenic therapy. This special issue will focus on new advancement in the biology and drug targeting of tumor angiogenesis.

We are looking forward to your contributions.

Dr. Ruowen Ge  
*Guest Editor*





*cancers*



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI